Evidence map›Paper›PMID 39844745›Full record

ReviewESC heart failure2025

State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age.

Roy Rasalam, Andrew Sindone, Gary Deed, Ralph G Audehm, John J Atherton

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Roy RasalamEndocrinology and Diabetes Department, Alfred Health, Melbourne, Victoria, Australia.
Andrew SindoneConcord Hospital, University of Sydney, Sydney, New South Wales, Australia.
Gary DeedHealthCarePlus Medical Centre, Carindale, Queensland, Australia.
Ralph G AudehmFaculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
John J AthertonFaculty of Medicine, Royal Brisbane and Women's Hospital, University of Queensland, Herston, Queensland, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. HFpEF has a complex and heterogeneous pathophysiology with multiple co-morbidities contributing to its presentation. Establishing the diagnosis of HFpEF can be challenging. Two algorithms, the 'Heavy, 2 or more Hypertensive drugs, atrial Fibrillation, Pulmonary hypertension, Elderly age >60, elevated Filling pressures' (H

Indexed as

Heart FailurePrecision MedicineStroke VolumeVentricular Function, LeftHumansClinical algorithmsDiagnosisHeart failure with preserved ejection fractionManagementPhenotypesPrecision medicineSGLT2iSodium‐glucose co‐transporter 2 inhibitorsTreatment

Identifiers

PMID39844745
PMCPMC12055434

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.